Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Biogen Inc.

Hambrecht & Quist analyst Wole Fayemi downgraded Biogen Inc. to "underperform" from "hold" and reiterated a "buy" on

Centocor Inc.

after Phase III clinical setbacks for Ciba-Geigy's Hirudin. TIMI-9, the Phase III clinical program for Hirudin in angioplasty, and GUSTO II, the Phase III trial for

Read the full 488 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE